Peripheral Neuritis Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Rising economic burden and unmet treatment needs: The peripheral neuritis treatment market are growing due to the very high economic burden associated with conditions such as Diabetic Peripheral Neuropathic Pain (DPNP), which follows increased hospitalization and medication expenses after diagnosis. According to a study by NIH 2025, in China, acupuncture is administered in nearly 41.63% of cases, signifying the unspecific treatment approaches due to the very few treatment options available. This unmet clinical need is driving demand for advanced guideline-based therapies around the world so that patient outcomes may be improved, and the utilization of healthcare resources may be made economical.
- Expansion of evidence-based complementary therapies: The expanding clinical database for alternative therapies applied in chemotherapy-induced peripheral neuropathy (CIPN) helps enhance the global market growth further in market. According to a January 2023 MDPI report, up to 71% of patients receiving acute treatments like Oxaliplatin or Docetaxel develop chemotherapy-induced peripheral neuropathy (CIPN), which is a key reason why some choose to stop their treatment. This highlights the importance of developing integrative, patient-specific solutions within supportive care pathways for oncology.
- Advancements in diagnostic precision and research investments: Innovations in diagnostic tests and biomarkers continue to contribute to early detection and customized treatment of peripheral neuropathy treatment market. Some gene mutations have been found to cause hereditary neuropathies, with gene-based diagnostic and therapeutic solution development being undertaken by groups such as the Inherited Neuropathies Consortium. This progress is driving global demand for precision medicine, advanced imaging, and neurodiagnostic technologies. Thereby creating demand worldwide for precision medicine, high-end imaging, and neurodiagnostic technologies.
Mechanism of Action and Efficacy of Oral Pharmacological Agents for Painful Diabetic Peripheral Neuropathy
|
Drug Class |
Mechanism of Action |
Efficacy in RCTs |
|
SNRIs |
Block sodium channels; ↑ norepinephrine, serotonin, dopamine |
Duloxetine FDA-approved. Desvenlafaxine 200 & 400 mg ↑ pain relief (mean BGD in NPRS 1.10 & 0.91). Venlafaxine ER 150–225 mg showed 50% pain reduction vs 27% placebo (p<0.001). |
|
Gabapentinoids |
Block calcium-mediated neurotransmitter release |
Pregabalin FDA-approved. Gabapentin (900–3600 mg/day) ↑ pain relief by 1.2 points NPRS; 900 mg/day no significant effect in 6-week RCT. |
|
Sodium Channel Blockers |
Block voltage-sensitive sodium channels, other ion channels |
Lacosamide 400 mg ↑ pain relief (two 18-week RCTs). Lamotrigine 400/600 mg ↑ pain relief (6-week & 19-week RCTs). Oxcarbazepine 300–1800 mg effective (16-week RCT). Valproic acid 500 mg is effective at 1 month, sustained to 3 months. |
Source: NLM March 2024
Challenges
- Fragmented and non-standardized treatment landscape: The global peripheral neuritis treatment ecosystem remains fragmented to the extent that no universally accepted clinical protocol exists across geographies. In the China-based study, only a subset of treated patients received antidepressants, despite their recognition in international guidelines as a frontline option for managing neuropathic This denotes contradictory provider education, therapeutic inertia, and regulatory inconsistencies, which hinder the unification of market development and thereby hamper the adoption of advanced therapies.
- Underinvestment in mechanism-based drug development: While analgesics and anti-inflammatories remain the top in prescribing, these drugs only serve as symptomatic relief for neuroinflammation or axonal degeneration in the peripheral neuritis treatment market. The market is devoid of disease-modifying agents, and existing R&D pipelines are hamstrung by high failure rates in clinical trials, lack of biomarker validation, and uncertain reimbursement outlooks. With such impediments come lengthier commercialization timelines, and investors are discouraged.
Peripheral Neuritis Treatment Market: Key Insights
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.5% |
|
Base Year Market Size (2025) |
USD 2.1 billion |
|
Forecast Year Market Size (2035) |
USD 3.5 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of the peripheral neuritis treatment market is estimated to reach approximately USD 2.1 billion.
The market size for the peripheral neuritis treatment market is projected to reach around USD 5.5 billion by the end of 2035, rising at a CAGR of about 5.5% during the forecast period (2026–2035).
The major global players in the market include Pfizer Inc., Eli Lilly & Company, Abbott Laboratories, Janssen Pharmaceuticals (Johnson & Johnson), and others.
Oral treatment modalities are expected to gain the largest share, accounting for approximately 62% of the Route of Administration segment by 2035.
The market in North America is expected to continue dominating the forecast period, accounting for a significant share of approximately 40%.
